Literature DB >> 23764799

Can we alter the natural history of osteoarthritis after SCFE with early realignment?

John M Wiemann1, José A Herrera-Soto.   

Abstract

In situ fixation has been the gold standard for the treatment of slipped capital femoral epiphysis for some time. This technique has been popular despite obligate residual proximal femoral deformity due to the increased risk for catastrophic avascular necrosis of the femoral head with closed manipulation and historical open reduction techniques. As the body of evidence regarding long-term outcome has grown, it has become evident that early osteoarthritis is common after in situ or conservative treatment because of femoroacetabular impingement of the deformed femoral neck on the acetabular rim. New techniques have been developed that show promise in preventing the early onset of osteoarthritis while minimizing the risk of avascular necrosis with early realignment of the proximal femoral anatomy and elimination of femoroacetabular impingement.

Entities:  

Mesh:

Year:  2013        PMID: 23764799     DOI: 10.1097/BPO.0b013e318277167b

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  3 in total

1.  Risk factors for early symptomatic femoroacetabular impingement following in situ fixation of slipped capital femoral epiphysis.

Authors:  Melissa M Allen; Ramesh B Ghanta; Matthew Lahey; Scott B Rosenfeld
Journal:  J Clin Orthop Trauma       Date:  2022-04-01

2.  Arthroscopic osteochondroplasty in patients with mild slipped capital femoral epiphysis after in situ fixation.

Authors:  Philippe M Tscholl; Patrick O Zingg; Claudio Dora; Eric Frey; Stefan Dierauer; Leonhard E Ramseier
Journal:  J Child Orthop       Date:  2015-11-20       Impact factor: 1.548

3.  Fate of patients with slipped capital femoral epiphysis (SCFE) in later life: risk of obesity, hypothyroidism, and death in 2,564 patients with SCFE compared with 25,638 controls.

Authors:  Yasmin D Hailer
Journal:  Acta Orthop       Date:  2020-04-14       Impact factor: 3.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.